Drew Rasco practices Hematology. He attended University of Texas Southwestern Medical School. Drew Rasco is also a published physician. He has 14 publication published. The most recent publication is: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer. He is registered with Medicare and accepts Medicare payments.
|
Dr. Edgar A. Castillo Dandreis, MD
|
|
Dr. Lindsay L. Peterson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gregory J. Guzley, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Edsel L. Hesita, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Manuel A. Santiago, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sukeshi R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Allyson L. Harroff, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Carl R. Meier, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. James B. Ellis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alexei Arkhipov, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David J. Haile, MD
|
|
Dr. Frederick L. Flynt Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph My, DO
|
|
Dr. Rogelio I. Gonzalez, MD
|
|
Dr. Arun R. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael A. Wiggins, MD
|